These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25794980)

  • 1. Meet Me in Computed Tomography Suite: Decreasing Tissue Plasminogen Activator Door-to-Needle Time for Acute Ischemic Stroke Patients.
    Speirs L; Mitchell A
    J Emerg Nurs; 2015 Sep; 41(5):381-6. PubMed ID: 25794980
    [No Abstract]   [Full Text] [Related]  

  • 2. Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
    Schrock JW; Lum M
    Am J Emerg Med; 2014 Nov; 32(11):1330-3. PubMed ID: 25195044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regarding "Meet Me in Computed Tomography Suite: Decreasing Tissue Plasminogen Activator Door-to-Needle Time for Acute Ischemic Stroke Patients".
    Gutierrez EP
    J Emerg Nurs; 2016 Jan; 42(1):5. PubMed ID: 26825503
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
    Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
    Fonarow GC; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Grau-Sepulveda MV; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
    Circulation; 2011 Feb; 123(7):750-8. PubMed ID: 21311083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in Door-to-Needle Time in Patients with Acute Ischemic Stroke via a Simple Stroke Activation Protocol.
    Tan BYQ; Ngiam NJH; Sunny S; Kong WY; Tam H; Sim TB; Leong BSH; Bhartendu C; Paliwal PR; Seet RCS; Chan BPL; Teoh HL; Sharma VK; Yeo LLL
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1539-1545. PubMed ID: 29422380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Impact of Implementation of a Stroke Protocol on Door-to-Needle Time in the Administration of Intravenous Tissue Plasminogen Activator.
    Hillen ME; He W; Al-Qudah Z; Wang W; Hidalgo A; Walia J
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1569-1572. PubMed ID: 28411038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in IV t-PA door to needle times using an Acute Stroke Triage Pathway.
    Mehdiratta M; Woolfenden AR; Chapman KM; Johnston DC; Schulzer M; Beckman J; Teal PA
    Can J Neurol Sci; 2006 May; 33(2):214-6. PubMed ID: 16736733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using LEAN methodology to expedite the treatment of acute ischemic stroke in the emergency room.
    Balcom C; Reyes E
    Healthc Manage Forum; 2019 Sep; 32(5):232-236. PubMed ID: 31146588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of emergency department crowding on the efficiency of care for acute stroke patients.
    Tsai MT; Yen YL; Su CM; Hung CW; Kung CT; Wu KH; Cheng HH
    Int J Qual Health Care; 2016 Dec; 28(6):774-778. PubMed ID: 27678127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan.
    Tanaka K; Matsumoto S; Yamada T; Nagano S; Takase KI; Hatano T; Yamasaki R; Kira JI
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104305. PubMed ID: 31405791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department.
    ; Brown MD; Burton JH; Nazarian DJ; Promes SB
    Ann Emerg Med; 2015 Sep; 66(3):322-333.e31. PubMed ID: 26304253
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience.
    Chapman KM; Woolfenden AR; Graeb D; Johnston DC; Beckman J; Schulzer M; Teal PA
    Stroke; 2000 Dec; 31(12):2920-4. PubMed ID: 11108749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke.
    Xian Y; Smith EE; Zhao X; Peterson ED; Olson DM; Hernandez AF; Bhatt DL; Saver JL; Schwamm LH; Fonarow GC
    Stroke; 2014 May; 45(5):1387-95. PubMed ID: 24713527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Door-to-Needle Times for Acute Ischemic Stroke: Effect of Rapid Patient Registration, Moving Directly to Computed Tomography, and Giving Alteplase at the Computed Tomography Scanner.
    Kamal N; Holodinsky JK; Stephenson C; Kashayp D; Demchuk AM; Hill MD; Vilneff RL; Bugbee E; Zerna C; Newcommon N; Lang E; Knox D; Smith EE
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational Multicenter Study of a Direct-to-CT Protocol for EMS-transported Patients with Suspected Stroke.
    Cone DC; Cooley C; Ferguson J; Harrell AJ; Luk JH; Martin-Gill C; Marquis SW; Pasichow S
    Prehosp Emerg Care; 2018; 22(1):1-6. PubMed ID: 28841085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.
    Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K
    Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organizational changes aiming to reduce iv tPA door-to-needle time.
    Thortveit ET; Bøe MG; Ljøstad U; Mygland A; Tveiten A
    Acta Neurol Scand; 2014 Oct; 130(4):248-52. PubMed ID: 24256431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing door-to-needle time for tPA use remains an elusive goal in stroke care.
    Mitka M
    JAMA; 2011 Apr; 305(13):1288-9. PubMed ID: 21467278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.